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Available online 29 July 2015AbstractThe worldwide prevalence of hepatocellular carcinoma (HCC) is substantially increasing. Approximately 50% of all cases occur in China.
However, more than 85% of cases are diagnosed at an advanced disease stage, thus missing the effective treatment window. Currently, the 5-year
survival rate for HCC patients is less than 15%. Despite the use of new therapeutic strategies for HCC in clinical practice. The metabolic
syndromes and human immunodeficiency virus (HIV) infections are to be considered as new HCC high-risk-population. Furthermore, liver
cirrhosis patients with HBV mutations or with cirrhotic nodules are regarded as HCC extremely high-risk populations. This mini-review provides
an overview of HCC new high-risk populations and of stratified screening strategies that are based on the latest clinical studies.
© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Beijing You’an Hospital affiliated to Capital Medical University. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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With the development of antiviral drugs, hepatitis C may
become a curable disease [1], and the outcome of hepatitis B
patients may improve [2]. The liver cirrhosis and hepatocel-
lular carcinoma (HCC) induced by hepatitis B and C were
decreased [3]. Planned immunization against HBV and
mother-infant HBV infection have been advocated in China in
the last 10 years, causing a significant reduction in the HBV-
related HCC incidence rate [4]. However, why is the world-
wide prevalence of HCC substantially increasing [5,6]?
Epidemiological studies have confirmed that diabetes, non-
alcoholic fatty liver disease (NAFLD) may be an indepen-
dent risk factor for HCC [7,8]. Recently, human immunode-
ficiency virus (HIV) infection, a new risk factor for HCC, has
been reported [9]. This mini-review provides an overview of
HCC new high-risk populations and of stratified screening
strategies that are based on the latest clinical studies.* Corresponding author. Tel.: þ86 10 83997155; fax: þ86 10 63295525.
E-mail address: dinghuiguo@medmail.com.cn (H. Ding).
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2352-6211/© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf
open access article under the CC BY-NC-ND license (http://creativecommons.org/2. HCC high-risk populations2.1. Chronic viral hepatitis with FH (þ)HBV and HCV infections play an important role in the
occurrence and development of HCC. It is estimated that 70%of
primary hepatocellular carcinomas are caused by HBVor HCV
infection [10]. A caseecontrol study in the USA found that the
risk of HCC in individuals whose first-degree relatives (parents,
children, siblings) had a family history ofHCC [FH (þ)] was 3.9
times that of individuals without HCC family history [19]. The
cumulative incidences of HCC over 17 years in the FH
(þ)/HBsAg (þ), FH ()/HBsAg (þ), FH (þ)/HBsAg (), and
FH ()/HBsAg () populations were 15.8%, 7.5%, 0.65%, and
0.62%, respectively [11]. Therefore, HBV infected individuals
with FH (þ) are regarded as high risk for HCC.2.2. Liver cirrhosisVarious causes of cirrhosis are currently recognized as
high-risk factors for HCC. Approximately 80e90% of HCC
occurred in liver cirrhosis patients. It has been estimated thatof Beijing You’an Hospital affiliated to Capital Medical University. This is an
licenses/by-nc-nd/4.0/).
Table 1
Comparison of recommendations for HCC surveillance in different guidelines.
Characteristics AASLD guideline [16] EASL guideline [26] APASL guideline [27]
HCC risk population (1) Cirrhotic patients with different etiology.
(2) HBV carriers of Asian origin
(male>40 yr, female > 50 yr).
(3) African/North American Blacks with hepatitis B.
(4) HBV carriers with family history of HCC.
(1) Cirrhotic patients with Child-Pugh stage A, B
and stage C awaiting liver transplantation.
(2) HBV carriers with active hepatitis
or family history of HCC.
(3) Chronic hepatitis C with advanced fibrosis F3.
Cirrhotic HBV
and HCV patients.
Surveillance benefit
uncertain patients
(1) HBV carriers younger than 40 (males)
or 50 (females).
(2) Hepatitis C patients with fibrosis F3.
(3) Non-cirrhotic NAFLD
No explanation No explanation
Surveillance modality US US US and AFP
Interval (mo) 6 6 6
AASLD: American Association for Study of Liver Disease; EASL: European Association for the Study of the Liver; APASL: Asian Pacific Association for the
Study of the Liver; HBV: hepatitis B virus; HCV: hepatitis C virus; NAFLD: non-alcoholic fatty liver disease; US: ultrasound; AFP: a-fetoprotein; HCC: he-
patocellular carcinoma.
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infection in China [5]. The annual incidence rate of HCC in
patients with decompensated hepatitis B-induced cirrhosis was
2e5% [12]. Currently, the international consensus is that
effective antiviral therapy can reduce the incidence of HCC in
patients with hepatitis B-related cirrhosis [13]. However, some
studies have showed that failure of the antiviral treatment or
viral resistance mutations increase the incidence of HCC [14].
An investigation in 38 European countries in 2006 showed that
drinking alcohol accounted for 9.4% of the risk among all risk
factors for HCC [15]. The incidence of HCC in patients with
stage-IV PBC is similar to that in patients with HCV-related
cirrhosis [16]. HCC was detected in 73.4% of patients with
micronodular cirrhosis, suggesting that HCC is closely asso-
ciated with cirrhotic liver nodules [17]. Therefore, liver
cirrhosis is considered to be a high-risk factor for HCC, and
patients with HBV mutations or antiviral failure or with
cirrhotic nodules (1 cm) are regarded as HCC extremely
high-risk population.2.3. Metabolic syndromesMetabolic syndromes include insulin resistance, obesity,
hypertension, and hyperlipidemia. Recently, a large-scale
epidemiological survey of 2897 Chinese individuals showed
that the incidence rate of diabetes in patients with HCC was
significantly higher than in healthy 40e60 year old individuals
(15.6% vs. 11.5%, respectively) [18].Therefore, metabolic
syndromes, especially in non-alcoholic steatohepatitis are
regarded as high risk for HCC and should be recommended for
HCC screening [19].2.4. HIV infectionAs a result of significant improvements in the efficacy of
highly active anti-retroviral therapy (t-HAART), HIV/AIDS
patient survival time has been prolonged. As a consequence,
concomitant malignancies have become an important cause of
death in HIV patients [20,21]. A prospective cohort study
recently demonstrated that the HCC incidence was 6.72/1000person-years in 371 cases of HIV infection with liver cirrhosis
(95% HCV and 9% HBV) [9]. Therefore, HIV-infected pa-
tients, especially those with HCV or HBV infections, are also
considered as HCC high risk population.2.5. Shortcomings of the current guidelines
recommendation for HCC screeningFor populations of HCC high risk, in European, United
States and AsiaePacific Region guidelines, HCC were
screened using B-ultrasound or combination with serum alpha-
fetoprotein (AFP) every 6 months, as shown in Table 1 [22].
However, this current screening program has some short-
comings. First, although AFP is widely accepted as a biolog-
ical marker for HCC diagnosis, the low sensitivity was
recently reported as a screen for HCC [23]. In addition,
30e40% of HCC patients were AFP-negative. Second,
although B-ultrasound has a sensitivity of 65.0e80.0% and a
specificity of 90.0% for HCC screening, this screening pro-
cedure depends on operator experience. Some new serological
diagnostic markers have been studied in recent years; they
include the lens culinaris agglutinin-reactive fraction of
AFP(AFP-L3), glypican-3(GPC3), des-g-carboxyprothrombin
(DCP), and golgi protein 73(GP73), all of which have been
employed for the screening and early diagnosis of HCC [24].
Its have limitations for the early diagnosis and screening of
HCC. Therefore, a reasonable stratification of the HCC high
risk population was performed.2.6. Stratified screening of HCC high risk populationsIn the last decade, there has been a marked increase in the
therapeutic options for HCC. Nevertheless, curative options
are only useful in the case of early detection. Currently, the 5-
year survival rate for HCC patients is less than 50%, despite
the use of new therapeutic strategies for HCC in clinical
practice [25]. One cohort study included 255 patients with
decompensated HBV-induced cirrhosis who were followed for
4 years. Some of these patients were screened for HCC at 3-
month intervals using serum AFP and GPC3, in combination
Table 2
The stratified screening strategies of HCC high risk populations.
Stratified HCC
risk populations
Low risk populations High risk populations Extremely high risk populations
Clinical
characteristics
(1) HBV carriers
with normal ALT.
(2) Metabolic syndrome
with normal ALT
and age < 50 yrs.
(3) Hepatitis C patients
with fibrosis < F3.
(1) HBV infection with FH (þ)
(2) CHB and age > 40yrs (males)
or 50 (females).
(3) Compensated cirrhotic patients.
(4) CHB patients with HBV mutations
(A1762T/G1764A).
(5) Alcoholic, metabolic syndrome,
autoimmune patients and sustained
abnormal ALT.
(6) HIV and HBV/HCV co-infection
and abnormal ALT.
(1) Cirrhotic nodules >1 cm with different etiology
(2) Cirrhotic patients with family history of HCC.
(3) Compensated cirrhotic patients with FH(þ).
(4) Decompensated HBV cirrhotic patients failure
to antiviral therapy.
(5) Cirrhotic patients and HBVA1762T/G1764A
mutations or antiviral resistance-related gene
mutations (rtA181T).
Screening modality US and AFP US and AFP US ,AFP and AFP-L3, GPC3,DCP,GP73
Interval (mo) 24 6 3
ALT: alanine transaminase; CHB: chronic active hepatitis B; FH(þ): family history of HCC of the first-degree relatives.
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tients was BCLC-A stage HCC, but only 5.9% of HCC in
patients performed the routine screening (6-month intervals
using AFP and/or B-ultrasonography) [28]. If serum AFP
levels increase, it is necessary to test other serum biomarkers
and to shorten the screening interval to 1e2 months. If B-ul-
trasound examination reveals an atypical hyperplastic nodule
with a diameter of >1 cm, a CT scan and/or an MRI are
strongly recommended for screening. Therefore, different
screening strategies were studied by stratifying the population
at high risk for HCC into 3 categories, low risk, high risk and
extremely high risk shown in Table 2. However, there is little
evidence for its effectiveness in clinical practice. The opti-
mization of screening programs should be studied in the
future. B-ultrasonography is the most promising tool for
screening, but the debate about serum biomarkers such as AFP
and screening interval length is not yet over.
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